XV | Jotup

Aroundtown SA notification of a change in major holdings pursuant to the modified law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities

Retrieved on:

Monday, February 5, 2024

Vii, Life, Exercise, Disclosure, Ix, XV, LEI, Name, Acquisition, Letter, Person, Security (finance)

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g.

Key Points:

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g.
iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.
As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g.
v Applicable in the cases provided for in Article 9 (b) to (h) of the Transparency Law.

Aroundtown SA notification of a change in major holdings pursuant to the modified law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities

Retrieved on:

Tuesday, January 30, 2024

Separate, Person, Life, Ix, International, Name, Vii, LEI, Acquisition, XV, Citigroup, Disclosure, Letter, Exercise, Security (finance)

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g.

Key Points:

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g.
iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.
As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g.
v Applicable in the cases provided for in Article 9 (b) to (h) of the Transparency Law.

Aroundtown SA notification of a change in major holdings pursuant to the modified law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities

Retrieved on:

Tuesday, January 30, 2024

Separate, Person, Life, Ix, International, Name, Vii, LEI, Acquisition, XV, Citigroup, Disclosure, Letter, Exercise, Security (finance)

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g.

Key Points:

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g.
iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.
As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g.
v Applicable in the cases provided for in Article 9 (b) to (h) of the Transparency Law.

Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023

Retrieved on:

Tuesday, January 9, 2024

Table, Patient, Research, Accounting, 600 (number), SAN, Civil service commission, European Commission, Risk, GAAP, Acquisition, XV, Conference, Webcast, Organization, Government, Eastern Time Zone, Security (finance), Growth

SAN DIEGO, Jan. 9, 2024 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2023 ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 at 9:00am Pacific Time (12:00pm Eastern Time).

Key Points:

SAN DIEGO, Jan. 9, 2024 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2023 ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 at 9:00am Pacific Time (12:00pm Eastern Time).
The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com.
Consolidated revenue of approximately $1,115 million for Q4 2023, up 3% from Q4 2022, and approximately $4,497 million for fiscal year 2023, down 2% from fiscal year 2022
Core Illumina revenue of approximately $1,090 million for Q4 2023, up 2% from Q4 2022, and approximately $4,431 million for fiscal year 2023, down 3% from fiscal year 2022
As previously announced, the company expects to report its full fourth quarter and fiscal year 2023 results following the close of market on Thursday, February 8, 2024.
The unaudited results in this press release are preliminary and subject to the completion of accounting and annual audit procedures and are therefore subject to adjustment.

Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

Retrieved on:

Wednesday, January 3, 2024

Failure, 600 (number), Risk, XV, Form, File, Common stock, Calendar, COVID-19, Nature, Form S-4, Letter, Growth, XXV, Indian stock exchange, Security (finance), Auction

BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it received notification (“Nasdaq Notification”) from The Nasdaq Stock Market LLC (“Nasdaq”) on December 29, 2023 indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Select Market (Nasdaq Listing Rule 5450(a)(1)).

Key Points:

Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price Requirement
BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it received notification (“Nasdaq Notification”) from The Nasdaq Stock Market LLC (“Nasdaq”) on December 29, 2023 indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Select Market (Nasdaq Listing Rule 5450(a)(1)).
The Nasdaq Notification has no immediate effect on the listing of the Common Shares on the Nasdaq Capital Market.
In accordance with the Nasdaq Notification, Homology has a compliance period of 180 calendar days from the date of the notification letter from Nasdaq, or until June 26, 2024, to regain compliance with the requisite minimum bid price requirement.
If, at any time before June 26, 2024, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten (10) consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement.

Aroundtown SA notification of a change in major holdings pursuant to the modified law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities

Retrieved on:

Saturday, December 30, 2023

LEI, JPMorgan Chase, Life, XV, Chase Bank, Acquisition, Separate, Person, National Association, Disclosure, Name, Letter, Ix, Vii, Exercise, Security (finance)

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g.

Key Points:

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g.
iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.
As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g.
v Applicable in the cases provided for in Article 9 (b) to (h) of the Transparency Law.

Aroundtown SA notification of a change in major holdings pursuant to the modified law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities

Retrieved on:

Saturday, December 30, 2023

LEI, XV, Acquisition, Person, Disclosure, Name, Letter, Ix, Vii, Exercise, Life, Security (finance)

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g.

Key Points:

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g.
iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g.
As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g.
v Applicable in the cases provided for in Article 9 (b) to (h) of the Transparency Law.

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2023

Retrieved on:

Thursday, November 9, 2023

Organic revenue for the fiscal fourth quarter of 2023 excludes the divested Blood Screening business.

Key Points:

Organic revenue for the fiscal fourth quarter of 2023 excludes the divested Blood Screening business.
These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP.
The Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of Hologic's historical operating results, comparison to competitors' operating results and determination of management incentive compensation.
ET today to discuss its financial results for the fourth quarter of fiscal 2023.

UNITED IS THE NEW GOLD: NEW CHIVAS REGAL ADVERTISING CAMPAIGN CELEBRATES THE POWER OF SHARED SUCCESS

Retrieved on:

Thursday, December 14, 2023

Chivas Regal, Ant, Glass, Golden hour, Gold rush, XV, Ice, New Gold, Partnership, McCann (company), Pernod Ricard, ReserveBar, SRP, OOH, Nightclub, Scotch, SCOTLAND, Cognac, United, Chivas

NEW YORK, Dec. 14, 2023 /PRNewswire/ -- Chivas Regal, an icon of luxury blended Scotch whisky, announces first US led national advertising campaign with United is the New Gold. As a brand with rich history that's always celebrated those who are redefining success on their own terms, Chivas' new campaign embarks to reimagine hustle-culture with a modern-day vision of aspiration: shared success.

Key Points:

NEW YORK, Dec. 14, 2023 /PRNewswire/ -- Chivas Regal, an icon of luxury blended Scotch whisky, announces first US led national advertising campaign with United is the New Gold.
As a brand with rich history that's always celebrated those who are redefining success on their own terms, Chivas' new campaign embarks to reimagine hustle-culture with a modern-day vision of aspiration: shared success.
Chivas has a heritage rooted in the shared success of its founders, a legendary duo who set the tone foundationally to zig against convention.
Centuries of expertise have gone into the ultra-prestigious whisky, and today the brand is resetting the tone with a new definition of success.

4DMedical and Imbio Merge to Create Comprehensive Cardiothoracic Image Analysis Portfolio

Retrieved on:

Monday, December 11, 2023

Lung, COPD, Acquisition, Pulmonary embolism, ILD, Patient, XV, Algorithm, Lung cancer, Diagnosis, Chronic obstructive pulmonary disease, Physician, Health, Smoking, Medical imaging, Veteran

LOS ANGELES, Dec. 11, 2023 /PRNewswire/ -- 4DMedical announces it has entered a binding agreement to acquire Imbio (a portfolio company of Minneapolis-based Invenshure). As the creators of groundbreaking lung imaging technologies, 4DMedical aims to revolutionize respiratory imaging and ventilation— for improved lung disease detection and management. Imbio technology complements those products perfectly, delivering quantitative and personalized imaging analysis for patients suffering from both acute and chronic diseases.

Key Points:

LOS ANGELES, Dec. 11, 2023 /PRNewswire/ -- 4DMedical announces it has entered a binding agreement to acquire Imbio (a portfolio company of Minneapolis-based Invenshure).
As the creators of groundbreaking lung imaging technologies, 4DMedical aims to revolutionize respiratory imaging and ventilation— for improved lung disease detection and management.
Imbio technology complements those products perfectly, delivering quantitative and personalized imaging analysis for patients suffering from both acute and chronic diseases.
Combining 4DMedical and Imbio existing technologies into a unified offering and development platform will drive respiratory health improvements around the globe.